Published in Tubercle on March 01, 1991
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother (1992) 3.72
In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1998) 3.02
Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother (1993) 2.97
Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother (1999) 2.54
Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother (1994) 2.34
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother (2006) 1.97
Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob Agents Chemother (1996) 1.88
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother (2006) 1.81
In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1995) 1.80
Activity of levofloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother (1994) 1.79
Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother (2003) 1.71
Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother (1997) 1.46
Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones. Antimicrob Agents Chemother (1994) 1.27
Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents Chemother (1994) 1.19
Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother (1993) 1.17
Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1995) 1.12
Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother (1998) 1.04
Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One (2011) 1.04
In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob Agents Chemother (1994) 0.99
Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. Antimicrob Agents Chemother (1995) 0.99
Resistance status of Mycobacterium tuberculosis on the island of Crete, Greece. Eur J Clin Microbiol Infect Dis (2007) 0.75
Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis (1991) 4.74
Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother (2005) 3.81
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother (1992) 3.72
The challenge of tuberculosis: statements on global control and prevention. Lancet (1995) 3.19
In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1998) 3.02
Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother (1993) 2.97
Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis (2003) 2.92
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother (2005) 2.74
Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis (1992) 2.55
Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother (1990) 2.46
Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother (1994) 2.34
Tuberculous meningitis in France in 1990: characteristics and impact of BCG vaccination. Tuber Lung Dis (1994) 2.21
Recent advances in the chemotherapy of leprosy. Lepr Rev (1990) 2.11
Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother (1991) 2.08
Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis (1993) 2.07
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother (2001) 1.98
Impact of BCG on tuberculous meningitis in France in 1990. Lancet (1992) 1.97
The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc (1978) 1.92
Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother (2001) 1.90
[Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)]. Pathol Biol (Paris) (1982) 1.90
Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis (2004) 1.89
In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1995) 1.80
Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother (2000) 1.79
In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle (1991) 1.77
Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother (1991) 1.77
Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med (1980) 1.76
Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tuber Lung Dis (1994) 1.71
Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis (1995) 1.71
A prospective study of protected bronchoalveolar lavage in the diagnosis of nosocomial pneumonia. Anesthesiology (1989) 1.64
Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis (1994) 1.60
Preparation by two-dimensional electrophoresis of proteins for antibody production: antibodies against proteins whose synthesis is reduced by auxin in tobacco mesophyll protoplasts. Electrophoresis (1988) 1.55
A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Azay Mycobacteria Study Group. Tuber Lung Dis (1996) 1.49
Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. Lepr Rev (1998) 1.46
Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother (1997) 1.46
Leprosy and BCG in southern Vietnam. Lancet (1990) 1.44
Results of blood cultures for detection of mycobacteria in AIDS patients. Tubercle (1989) 1.43
Ofloxacin for the treatment of leprosy. Acta Leprol (1991) 1.41
Adverse effects of rifampin. Rev Infect Dis (1983) 1.40
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med (1994) 1.35
A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries. Microb Drug Resist (2005) 1.33
Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med (1993) 1.32
Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med (1998) 1.30
Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet (2001) 1.28
Iron and Mycobacterium tuberculosis infection. J Clin Virol (2001) 1.28
Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Lancet (1997) 1.28
CCK independently activates intracellular trypsinogen and NF-kappaB in rat pancreatic acinar cells. Am J Physiol Cell Physiol (2001) 1.24
Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agents Chemother (1992) 1.22
Is PCR a useful tool for the diagnosis of tuberculosis in 1995? Tuber Lung Dis (1995) 1.22
[Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse]. Rev Mal Respir (1985) 1.15
Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med (1999) 1.15
Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection). Eur Respir J (1992) 1.13
Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. Am J Respir Crit Care Med (2000) 1.13
Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1995) 1.12
Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease. Eur Respir J (2005) 1.12
Clinical utility of an amplification test based on ligase chain reaction in pulmonary tuberculosis. Am J Respir Crit Care Med (1998) 1.11
Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice. Int J Lepr Other Mycobact Dis (1994) 1.10
Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. J Antimicrob Chemother (1995) 1.09
Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrob Agents Chemother (2010) 1.08
Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice. Antimicrob Agents Chemother (1992) 1.07
Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother (1992) 1.06
Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group. Int J Tuberc Lung Dis (2000) 1.06
Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother (1998) 1.04
Surveillance of drug resistance for tuberculosis control: why and how? Tuber Lung Dis (1995) 1.03
New antibacterial drugs for the treatment of mycobacterial disease in man. Br Med Bull (1988) 1.02
Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother (2000) 1.02
[Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse]. Rev Fr Mal Respir (1983) 1.00
A national survey of human Mycobacterium bovis infection in France. Network of Microbiology Laboratories in France. Int J Tuberc Lung Dis (1999) 1.00
Glutathione S-transferase genotypes and stomach cancer in a population-based case-control study in Warsaw, Poland. Pharmacogenetics (2001) 0.99
Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. Antimicrob Agents Chemother (1995) 0.99
Multidrug resistant tuberculosis in France 1992-4: two case-control studies. BMJ (1998) 0.98
Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model. Tubercle (1967) 0.98
[Trial B.C.G. vaccination without previous tuberculin test in an Algiers outpatient clinic]. Rev Tuberc Pneumol (Paris) (1968) 0.95
Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. Antimicrob Agents Chemother (1993) 0.95
Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. Int J Tuberc Lung Dis (2003) 0.94
[Tuberculosis due to Mycobacterium africanum in African negroes in the Paris area]. Rev Tuberc Pneumol (Paris) (1971) 0.94
Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Clin Exp Immunol (1989) 0.93
Culture-independent prediction of isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum samples. Mol Diagn (1999) 0.92
Establishment of a novel rat model without blood priming during normothermic cardiopulmonary bypass. Perfusion (2013) 0.90
Effects of retrograde autologous priming on blood transfusion and clinical outcomes in adults: a meta-analysis. Perfusion (2013) 0.90
Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a large urban hospital: detection of outbreaks in homeless people and migrant workers. Int J Tuberc Lung Dis (1998) 0.89
Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. Antimicrob Agents Chemother (1995) 0.89
Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. Antimicrob Agents Chemother (1993) 0.88
[Activity of rifampicin administered daily and intermittently on experimental tuberculosis in mice]. Pathol Biol (Paris) (1983) 0.88
Determination of the minimal effective dosages of ofloxacin and sparfloxacin against M. leprae in the mouse foot pad system. Int J Lepr Other Mycobact Dis (1996) 0.87
[Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare]. Rev Mal Respir (1988) 0.86
Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev (2000) 0.86
Dysfunction of fronto-limbic brain circuitry in depression. Neuroscience (2011) 0.85
In-vitro activity of FCE 22101 and other beta-lactam antibiotics against Enterobacteriaceae resistant to third generation cephalosporins. J Antimicrob Chemother (1989) 0.85
The management of thirty immunocompromised patients with tuberculosis. Am Rev Respir Dis (1984) 0.84
The role of low dosage prothionamide with and without 4,4'-diamino diphenyl sulphone for use with isoniazid in the treatment of experimental mouse tuberculosis. Tubercle (1982) 0.83
Survey of the phenotypes of susceptibility to beta-lactams in Enterobacteriaceae at the Pitie-Salpetriere Hospital. J Antimicrob Chemother (1984) 0.83
Intermittent chemotherapy with isoniazid and streptomycin in Algiers. Tubercle (1967) 0.83